Júlio Oliveira (Julio Oliveira)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Brain Metastases

Small Cell Lung Cancer

Top Venues

International journal of molecular sciences

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Beatriz Almeida, Tânia R Dias, Pedro Cruz, Mário Sousa-Pimenta, Ana Luísa Teixeira, Catarina Esteves Pereira, Bruno Costa Silva, Júlio Oliveira, Rui Medeiros, Francisca Dias
Plasma EV-miRNAs as Potential Biomarkers of COVID-19 Vaccine Immune Response in Cancer Patients. Vaccines 12 (8) (2024)
Marta Pina Fernandes, Cristina Oliveira, Hugo Sousa, Júlio Oliveira
New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. International journal of molecular sciences 24 (4) (2023)
Marta Pina Fernandes, Cristina Oliveira, Hugo Sousa, Júlio Oliveira
New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. International journal of molecular sciences 24 (4) (2023)
Marta Pina Fernandes, Cristina Oliveira, Hugo Sousa, Júlio Oliveira
New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. International journal of molecular sciences 24 (4) (2023)
Cascone Tina, Gozde Kar, Jonathan D Spicer, María Del Rosario García-Campelo, Walter Weder, Davey B Daniel, David R Spigel, Maen Hussein, Julien Mazieres, Júlio Oliveira, Edwin H Yau, Alexander I Spira, Valsamo Anagnostou, Raymond Mager, Oday Hamid, Lin-Yang Cheng, Ying Zheng, Jorge M Blando, Tze Heng Tan, Michael Surace, Jaime Rodriguez-Canales, Vancheswaran Gopalakrishnan, Bret R Sellman, Italia Grenga, Yee Soo-Hoo, Rakesh Kumar, Lara McGrath, Patrick M Forde
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial. Cancer discovery (2023)
Marta Pina Fernandes, Cristina Oliveira, Hugo Sousa, Júlio Oliveira
New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. International journal of molecular sciences 24 (4) (2023)
Marta Pina Fernandes, Cristina Oliveira, Hugo Sousa, Júlio Oliveira
New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. International journal of molecular sciences 24 (4) (2023)
Tânia R Dias, Francisca Dias, Ana Luísa Teixeira, Hugo Sousa, Júlio Oliveira, Rui Medeiros
MicroRNAs as Potential Tools for Predicting Cancer Patients' Susceptibility to SARS-CoV-2 Infection and Vaccination Response. Cells 11 (15) (2022)